Humphrey Tebit is a Senior Research & Development professional
with extensive experience in clinical study design, statistical analysis and building strong relationships within and between teams. Outgoing and articulate with excellent communications skills, Mr. Tebit possesses in-depth understanding of clinical research complimented by a proven ability to develop business through R&D activities. Fully bilingual in French and English, Mr. Tebit has worked with 3 generic pharmaceutical companies, 2 Contract Research Organizations (CRO) and 1 animal research institute.
As the founder of HT Pharmaceuticals, a solely owned consultancy, Mr. Tebit brings 19 years of experience (5 in North America, 10 in Europe and 4 in Africa) to bear in providing a range of clinical research services in pharmacokinetic BA/BE and phase I-III clinical end point studies and statistical support for pharmaceutical and biotechnology companies.
As Associate Director of Pharmacokinetics and Statistics at Biovail, a CRO focused on early clinical trials and bioanalysis, Mr. Tebit put together a cohesive team that enhanced the production of additional study designs for developing quotations for contracted studies. While as Director of Pharmaceutics for Cantest Biopharma Services, a bioanalytical laboratory that develops methods to analyze pre-clinical and clinical samples, he designed numerous BA/BE studies and statistically analyzed the data obtained. At Apotex, the number one generic pharmaceutical company in Canada, Mr. Tebit served as a Consultant for Clinical Development, working on clinical end point studies in respiratory, dermatology and allergic rhinitis therapeutic areas. Previous roles include Principal Biometrics Officer, Team Leader and Clinical Consultant at Merck Generics and Research Assistant at the Institute of Animal Research.
Mr. Tebit holds a B.Sc. (Hons) in Biochemistry from the University of Ilorin, Nigeria and an M.Sc. in Biometry (Applied Statistics) from the University of Reading, UK. He is a Member of the Canadian Society of Pharmaceutical Scientists (CSPS) and the American Association of Pharmaceutical Scientist (AAPS).
